We provide the first examination of mitochondrial DNA (mtDNA) variants and pulmonary function in older persons. Methods: Cross-sectional associations between mtDNA variants and pulmonary function were evaluated as a combined p-values meta-analysis, using data from two independent cohorts of older persons. The latter included white and black participants, aged ≥70 years, from the Lifestyle Interventions and Independence for Elders study (LIFE) (N = 1247) and the Health, Aging and Body Composition study (Health ABC) (N = 731), respectively. Pulmonary function included the forced expiratory volume in one-second as a Z-score (FEV1z) and the maximal inspiratory pressure (MIP) in cm of water. Results: In black participants, significant associations were found between mtDNA variants and MIP: m.7146A > G, COI (p = 3E-5); m.7389 T > C, COI (p = 2E-4); m.15301G > A, CYB (p = 9E-5); m.16265A > G, HV1 (p = 9E-5); meta-analytical p-values < 0.0002. Importantly, these mtDNA variants were unique to black participants and were not present in white participants. Moreover, in black participants, aggregate genetic effects on MIP were observed across mutations in oxidative phosphorylation complex IV (p = 0.004), complex V (p = 0.0007), and hypervariable (p = 0.003) regions. The individual and aggregate variant results were significant after adjustment for multiple comparisons. Otherwise, no significant associations were detected for MIP in whites or for FEV1z in whites or blacks. Conclusions: We have shown that mtDNA variants of African origin are cross-sectionally associated with MIP, a measure of respiratory muscle strength. Thus, our results establish the rationale for longitudinal studies to evaluate whether mtDNA variants of African origin identify those at risk of subsequently developing a respiratory muscle impairment (lower MIP values).
Introduction
A respiratory impairment in older persons is most often established by spirometry, in particular the forced expiratory volume in 1 s (FEV1) Pellegrino et al., 2005) . A decreased FEV1 usually denotes impaired respiratory mechanics (e.g. airflow obstruction) and is associated with adverse health outcomes Pellegrino et al., 2005; Enright et al., 1994; . In addition, because age-related sarcopenia and cardiorespiratory disease may decrease the force generating capacity of the diaphragm, a respiratory impairment may be established by a decreased maximal inspiratory pressure (MIP), a measure of respiratory muscle strength Sachs et al., 2009; Cruz-Jentoft et al., 2010) . A decreased MIP is likewise associated with adverse health https://doi.org/10.1016/j.exger.2018.11.023 Received 6 June 2018; Received in revised form 1 November 2018; Accepted 28 November 2018 outcomes (Sachs et al., 2009; Cruz-Jentoft et al., 2010; van der Palen et al., 2004; Vaz Fragoso et al., 2014) .
Twin studies suggest that genetic factors account for 32%-67% of the variance in pulmonary function and that the contribution of genetic factors to pulmonary function increases with age (McClearn et al., 1994) . Several genome-wide association studies of pulmonary function have identified a modest number of loci associated with these traits (Wain et al., 2017; Imboden et al., 2012; Yao et al., 2014; Ong et al., 2013; Tang et al., 2014) . However, the missing heritability in pulmonary function may be explained by rare genetic variants or genomic regions not examined as part of the genome-wide study, including variation in the mitochondrial genome.
Mitochondrial oxidative phosphorylation (OXPHOS) supplies 90% of human energetic requirements. This energy is supplied by a complex OXPHOS system that is dependent upon the coordinated expression and interaction of genes encoded in the nuclear and mitochondrial DNA (mtDNA). The majority of genes encoded by mtDNA are crucial for the machinery that converts metabolic energy into ATP, including 37 genes encoding polypeptides, tRNAs, and rRNAs. With a mutation rate 10-20 times higher than nuclear DNA (Wallace et al., 1997) , mtDNA is most appropriately studied via complete sequencing, as collections of common and rare variants have been shown to influence phenotypes in numerous ways (Schork et al., 2009) . Although common and rare mtDNA variants have been shown to contribute to several diseases and aging-related traits (Tranah et al., 2012; Katzman et al., 2015; Lam et al., 2012; Tranah et al., 2014; Tranah et al., 2015) , there is a paucity of research examining associations between mtDNA variants and pulmonary function.
In the current study, we provide the first examination of mitochondrial genomic variation and pulmonary function in older persons. Our objective was to perform a combined p-values meta-analysis, using data from two independent cohorts of older persons. The latter included white and black participants, aged ≥70 years, from the Lifestyle Interventions and Independence for Elders study (LIFE) (N = 1247) and the Health, Aging and Body Composition study (Health ABC) (N = 731) (Fielding et al., 2011; Rejeski et al., 2005; Visser et al., 2002) . Pulmonary function included the FEV1 as a Z-score (FEV1z) and the MIP in cm of water, both evaluated as continuous variables and with results stratified by white and black race (i.e., race is a predictor of pulmonary function) Pellegrino et al., 2005; Quanjer et al., 2012) . In secondary analyses, we additionally evaluated FEV1z and MIP as categorical variables (< lower limit of normal). We hypothesized that mtDNA variants are associated with pulmonary function, potentially identifying those at risk of having a respiratory impairment and new therapeutic targets.
Methods

Study populations
We evaluated two independent, well-characterized cohorts of older persons, specifically the LIFE and Health ABC studies (Fielding et al., 2011; Rejeski et al., 2005; Visser et al., 2002) .
LIFE was a multicenter, single-blinded, parallel randomized trial, having enrolled 1635 participants at 8 field centers across the U.S. between February 2010 and December 2013. LIFE included persons aged 70-89 years who: (a) were inactive (< 20 min/week in the past month performing regular physical activity and < 125 min/week of moderate physical activity); (b) were at high risk for mobility disability based on lower extremity functional limitations measured by the Short Physical Performance Battery (SPPB) (Guralnik et al., 1995) score ≤ 9; (c) could walk 400 m in ≤15 min without sitting, leaning, or the help of another person or walker; (d) had no major cognitive impairment; and (e) could safely participate in a moderate physical activity intervention.
Health ABC enrolled participants from two field centers between 1997 and 1998. Health ABC included 3075 persons aged 70-79 years who self-reported: (a) no difficulty in walking a distance of 0.4 km or climbing at least 10 stairs; (b) independence in activities of daily living; (c) had plans to live in the area for 3 years; and (d) had no life-threatening illnesses. As per study design, Health ABC enrolled a similar frequency of blacks and whites, and females and males.
The institutional review board at all field sites approved each study protocol and written informed consent was obtained from all study participants. LIFE is registered at ClinicalsTrials.gov (NCT01072500 and NCT00116194).
Baseline characteristics
Age, self-designated race/ethnicity and sex (fixed set of options), body mass index (BMI, kg/m 2 ), smoking status (never-and eversmoker), and self-reported, physician diagnosed chronic conditions were recorded at baseline. Ever-smoker included a history of ≥100 cigarettes smoked.
Pulmonary function
Participants underwent spirometry at baseline, using protocols from the American Thoracic Society (ATS) (Pellegrino et al., 2005; Vaz Fragoso et al., 2014; Health, 1998) . The spirometric measure of interest was the FEV1, specifically the highest value recorded during at least two ATS-acceptable spirometric maneuvers Pellegrino et al., 2005; Enright et al., 1994; . For comparisons between measured and predicted FEV1 values, we calculated Z-scores using reference equations from the Global Lung Function Initiative (GLI) Vaz Fragoso et al., 2014; Quanjer et al., 2012) . A Z-score for FEV1 (FEV1z) of −1.64 defined the lower limit of normal (LLN) as the 5th percentile of distribution Vaz Fragoso et al., 2014; Quanjer et al., 2012) . Participants were classified as having a respiratory impairment if FEV1z was < LLN Vaz Fragoso et al., 2014; Quanjer et al., 2012) .
The MIP was also evaluated at baseline, based on the performance of up to five MIP trials (Sachs et al., 2009; Vaz Fragoso et al., 2014; Health, 1998) . For comparisons between measured and predicted MIP values, we used reference equations from the Multi-Ethnic Study of Atherosclerosis (MESA) to establish the LLN (5th percentile of distribution) (Sachs et al., 2009 ). Participants were classified as having a respiratory impairment (i.e., respiratory muscle weakness) if their highest MIP in cm of water was < LLN (Sachs et al., 2009; Vaz Fragoso et al., 2014) .
Mitochondrial DNA sequencing
MtDNA sequence variants were evaluated in 1377 LIFE participants and 788 Health ABC participants. DNA was extracted from buffy coat using whole blood collected from Health ABC participants at baseline and from LIFE participants at baseline or 12-month visit.
Complete mtDNA sequencing was performed using the next-generation sequencing Illumina MiSeq platform. Briefly, the entire mitochondrial genome is first amplified in two long-range PCR reactions (9.1 kb and 11.2 kb) spanning the entire human mtDNA genome using TaKaRa LA ("long and accurate") Taq DNA Polymerase. TaKaRa LA Taq DNA Polymerase combines Taq DNA polymerase and a DNA-proofreading polymerase, with 3′ → 5′ exonuclease activity to enable long and accurate PCR amplification of DNA targets. The size distribution of each PCR amplicon is then verified using an Agilent Technologies 2100 Bioanalyzer. Using the Nextera XT DNA sample Preparation kit, designed specifically for human mtDNA, the PCR amplicons were simultaneously fragmented and tagged with adapter sequences. Prior to sequencing, each sample is amplified using a limited-cycle PCR program that adds unique indexes to each sample for a total of 384 indexes per sequencing run. In preparation for cluster generation and sequencing, equal volumes of bead-based normalized library are combined, diluted in hybridization buffer, and heat denatured prior to MiSeq sequencing. After sequencing and alignment to the Cambridge reference sequence (NC_12920), sequence processing is accomplished with the MiSeq Reporter and the mtDNA Analysis Tool for variant calling. For variant calling we specified a Q30 quality score (Q-score) which has a 0.1% error rate and an Analytic Threshold of 0.1 for making base calls. Multiplex-sequencing of 384 barcoded samples yielded an average depth of coverage > 250× and a minimum of 100× per individual.
Statistical analysis
Genetic associations followed established norms for performing a meta-analysis (Evangelou et al., 2014; Kraft et al., 2009; Skol et al., 2007; Nguyen et al., 2009; Cantor et al., 2010; Gogele et al., 2012) . This included evaluating genetic associations, first in the LIFE cohort and then replicated in the Health ABC cohort, followed thereafter by a combined p-values meta-analysis. The meta-analysis evaluates the heterogeneity of genetic effect across studies and reduces the probability of false-negatives and winner's curse phenomenon (Ioannidis et al., 2007; Higgins et al., 2003) .
Using a generalized linear model and allele thresholds set to 4% carrier frequency (CF), the continuous measures of FEV1z and MIP were first compared between major and minor alleles for individual mtDNA variants in both LIFE and Health ABC. Next, using unconditional logistic regression models, the odds ratios (ORs) and 95% confidence intervals (CIs) of having a respiratory impairment, defined categorically by FEV1z < LLN and MIP < LLN, respectively, were additionally calculated for individual mtDNA variants in both LIFE and Health ABC. Thereafter, combined p-values meta-analyses of FEV1z and MIP results were performed using METAL (Willer et al., 2010) with a fixed effects model using the inverse-variance weighting method. Because fixed effects meta-analysis assumes that true effect-size is constant across studies the degree of between-study heterogeneity was determined by Cochran's Q-test and I 2 index. All analyses were stratified by white and black race and adjusted for age, sex, and smoking status, using custom R scripts and SAS version 9.4 (SAS Institute Inc., Cary, NC). The Sequence Kernel Association Test (SKAT) (Wu et al., 2010 ) was also applied, and is designed for resequencing data where rare mutations are observed directly. The SKAT method has higher power than alternative methods for genetic burden analyses (aggregate effects across mutations) (Wu et al., 2010) and has previously been used for mtDNA sequence analysis (Giorgi et al., 2016; Tseng et al., 2018) . The SKAT test was developed based on random effect models, which assumes a common distribution for the genetic effects of variants at different sites and tests for the null hypothesis that the distribution has zero variation. Specifically, in the current study, SKAT was applied in association tests involving continuous FEV1z and MIP measures and computed the statistical significance for each test, using 10,000 independent simulations. For SKAT testing, a 'hierarchy' of annotations within 7 mtDNA regions was considered in order to refine the influence of collections of rare and common variants, including: each of four OXPHOS complexes (I, III, IV, and V); two rRNAs; all tRNAs combined; and combined hypervariable (HV) regions.
Notably, the above associations were examined for all variants in both white and black participants from LIFE and Health ABC. To account for population stratification, all analyses were adjusted for 6 eigenvectors of mitochondrial genetic ancestry derived from principal component analysis (PCA). In prior mtDNA sequencing work, the first 6 eigenvectors accounted for > 70% of the variance in the mtDNA sequence dataset (Tranah et al., 2011) .
Lastly, the in silico PhyloP (Pollard et al., 2010) method examined mtDNA nucleotide conservation, as none of the subsequent associated variants conferred nonsynonymous substitutions. In brief, phyloP performs multiple alignments of 100 vertebrate species and calculates metrics of evolutionary conservation for each variant under a null hypothesis of neutral evolution. The absolute values of phyloP scores represent -log p-values wherein positive scores reflect evolutionary conservation across taxa (slower rates than expected) and negative scores reflect accelerated evolution (faster than expected). Table 1 reports characteristics of the LIFE and Health ABC study samples. On average, LIFE participants were older, had greater representation of whites and females, higher proportion of morbid obesity and health conditions, more depressive symptoms, but lower proportion of ever-smokers. Of the 1377 LIFE participants with complete mtDNA sequencing, 1149 had FEV1z values and 1169 had MIP values. Of the 788 Health ABC participants with complete mtDNA sequencing, 731 had FEV1z values and 695 had MIP values. On average, LIFE participants had a lower FEV1z and MIP, and higher proportion of FEV1z < LLN and MIP < LLN.
Results
The sequencing of~16,5 kb of mtDNA from LIFE and Health ABC participants yielded a total of 3364 variants including: 89 common variants (CF, > 5%); 459 low frequency variants (CF, 1%-5%); and 2816 rare variants (CF, < 1%). Among white participants, a total of 103 independent mtDNA variants with CF ≥ 4% were examined for associations with pulmonary function, resulting in a Bonferroni adjusted Among black participants, a total of 216 independent mtDNA variants with CF ≥4% were examined for associations with pulmonary function, resulting in a Bonferroni adjusted p = 0.0002 for significance that accounted for multiple comparisons. Table 2 reports meta-analytic variant associations with FEV1z as a continuous measure. Three mtDNA variants were nominally associated with FEV1z in white participants and ten mtDNA variants were nominally associated with FEV1z in black participants. None of these variants were statistically significant after Bonferroni adjustment for multiple comparisons. Table 3 reports meta-analytic variant associations with MIP as a continuous measure. Among white participants from both study samples, one common mtDNA variant (m.16296C > T, HV1) was nominally associated with FEV1z, but not statistically significant after adjustment for multiple comparisons. Among black participants from both study samples, twelve common mtDNA variants were associated with a decreased or increased MIP, of which four were statistically significant after adjustment for multiple comparisons (Table 3 Table 4 reports meta-analytic variant associations with FEV1z < LLN and MIP < LLN, respectively. A nominally reduced risk of having MIP < LLN was observed for the m.5460G > A variant in white participants from both study samples, as well as in black participants from Health ABC. This association was not statistically significant after adjustment for multiple comparisons. Of note, the number of black LIFE participants who had MIP < LLN was limited (n = 37) and none carried the variant m.5460A allele. In addition, no associations with FEV1z < LLN reached statistical significance in white or black participants. There was no evidence of between-study heterogeneity for each within-race analysis (Q test) ≥0.05, I 2 < 50%.
Using SKAT, statistically significant aggregate effects on MIP (p = 0.007 due to multiple test correction for 7 mtDNA regions) were observed across OXPHOS complex IV (p = 0.004), complex V In silico prediction methods focused on nucleotide conservation generated via phyloP, as none of the associated variants conferred nonsynonymous substitutions. Results showed that three of the MIP-associated variants were not highly conserved among multiple vertebrate taxa, i.e., these variants exhibited negative phyloP scores: m.7146A > G = −0.40, m.15301G > A = −14.9, and m.16265A > G = −1.3. A single variant associated with MIP exhibited a positive phyloP score, m.7389 T > C = 0.07, consistent with modest conservation at this site.
Discussion
In a combined p-values meta-analysis of two independent cohorts of older persons, our results suggest that mtDNA variants are associated with MIP, a measure of respiratory muscle strength. Specifically, in black participants, four loci were associated with MIP as a continuous variable: m.7146A > G, COI, m.7389 T > C, COI, m.15301G > A, CYB, and m.16265A > G, HV1. Importantly, these mtDNA variants were unique to black participants, and not present in white participants. Otherwise, associations with MIP as a continuous variable were not statistically significant in whites, and associations with FEV1z as a continuous or categorical variable were not statistically significant in whites or blacks.
Our MIP results potentially identify populations that differ in respiratory muscle strength (MIP), specific to mtDNA variants. For example, as shown in Fig. 3, We also note that the m.7389 T > C, COI and m.16265A > G, HV1 variants, which were associated with higher MIP values (increased respiratory muscle strength), are found in multiple sub-lineages of superhaplogroup L (L0, L1, and L3). Our observation that m.7389 T > C and m.16265A > G are associated with MIP, regardless of genomic or phylogenetic background, supports a role for these variants in mitochondrial function. There was minimal evidence for evolutionary conservation at these associated sites and no previously identified associations with mitochondrial diseases (http://www.mitomap.org, n.d.). Nevertheless, mitochondrial variants occurring in one of the OXPHOS complexes (m.7389 T > C, COI) may lead to impairment of the respiratory chain (electron transport chain [ETC]), affecting reactive oxygen species (ROS) production, ATP generation efficiency, or apoptosis (Langston & Ballard Jr., 1983; Ramsay & Singer, 1986; Li et al., 2003) . In addition, HV1 sequence variation (m.16265A > G) may be involved in regulating mtDNA copy number (Suissa et al., 2009) , which may impact the capacity of the muscle to generate force.
Significant pooled effects on MIP were observed in black participants across OXPHOS complexes IV and V, and the HV region. The 13 mtDNA encoded OXPHOS genes are essential to mitochondrial energy production (Wallace, 2010) , and collective genetic variation within complexes IV and V may be specifically related to impairment of the respiratory chain (ETC), ROS production, or ATP generation (Shoubridge, 2001; Jonckheere et al., 2008; Nijtmans et al., 2001) . Defects in complex IV are associated with Leigh Syndrome, hypertrophic cardiomyopathy, and myopathy (Shoubridge, 2001) . Defects in complex V are associated with ATP synthase deficiency and it has been proposed that mutations in ATP6 and ATP8 are associated with reduced complex V assembly and impaired ATP synthase function (Jonckheere et al., 2008; Nijtmans et al., 2001) .
Prior research provides strong evidence linking mitochondrial function to pulmonary function and health (Donati et al., 2001; de Grey, 1997; Picard et al., 2015; Miura et al., 2013; Nam et al., 2017; Prakash et al., 2017) . For example, diaphragmatic fatigue related to mitochondrial dysfunction may contribute directly to decreased diaphragmatic contractility and age-related declines in exercise capacity, oxygen consumption, and carbon dioxide production (Picard et al., 2015; Miura et al., 2013) . To date, however, a large, multi-ethnic examination of the role of mtDNA variation in pulmonary function in the elderly has not been conducted. The current work identified statistically significant associations of mtDNA variants with MIP that are unique to black participants. Overall, African populations represent the most ancient human group and exhibit the largest extent of mtDNA variation when compared with Asian-and European-populations. In the current study, we identified over twice as many common mtDNA variants in black participants, as compared with white participants. Thus, surveying the more polymorphic mitochondrial African genome may have yielded more informative loci related to the role of mitochondrial variation in respiratory muscle strength.
We note the lack of association between mitochondrial variants and FEV1z in black and white participants, suggesting that mitochondrial function may not have a prominent role regarding reductions in pulmonary function that are attributed to impairments in respiratory mechanics (e.g. airflow obstruction). This conclusion is premature, however, because our LIFE and Health ABC study samples included only a small number of participants with FEV1z < LLN (n = 186 and 89, respectively). Hence, future work should include larger study samples with FEV1z < LLN, including stratification by spirometry-confirmed chronic obstructive pulmonary disease (COPD). As discussed earlier, prior research suggests that a link may exist between mitochondrial dysfunction and respiratory diseases (Nam et al., 2017; Prakash et al., 2017) . This study had several strengths, including: complete mtDNA sequencing, allowing for an unbiased assessment of mitochondrial genomic variation; two independent, well-characterized cohorts of older persons, having participants from multiple ancestries; and assessments of both FEV1 and MIP. Limitations are acknowledged, including: small sample sizes, limiting statistical power when evaluating the LIFE and Health ABC cohorts separately and when evaluating the effect of individual rare variants; and the mtDNA variants identified in this study may not be causally related to MIP (i.e., based on crosssectional associations). Thus, replication cohorts are needed, including those with a substantially greater representation of older persons having FEV1 and MIP < LLN, respectively.
In conclusion, using data from two independent cohorts of older persons, our results suggest that mtDNA variants of African origin are associated with MIP, potentially identifying those at risk of developing a respiratory muscle impairment. Future larger studies are needed, however, to further evaluate associations between mtDNA variants and pulmonary function, especially regarding MIP.
